Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2010

View Archived Issues

Equispharm claims new kinase B-raf inhibitors

Novel antibacterial agents claimed by Pfizer

New antimalarial compounds described by South African scientists

Indian scientists disclose new HIV-1 reverse transcriptase inhibitors

Novel 5-HT6 receptor ligands claimed by Suven Life Sciences

Clinical evaluation of oseltamivir/zanamivir combination for seasonal influenza

Panobacumab efficacious in phase IIa trial in hospital-acquired and ventilator-associated pneumonia

Promising antisense oligonucleotide therapeutics for DMD disclosed

Roche to submit marketing application to FDA for trastuzumab-DM1 in breast cancer

FDA accepts Acrux's Axiron testosterone therapy NDA for review

Phase II data on sulopenem-based regimens for community-acquired pneumonia requiring hospitalization

Oral CoQ10 improves mitochondrial dysfunction in patients on statin therapy

Sanofi-aventis reports promising phase III data on lixisenatide in type 2 diabetes

Swedish Orphan Biovitrum receives distribution rights to Rhucin in agreement with Pharming

Theravance begins phase II trial of TD-1211 for opioid-induced constipation

Trevena begins phase I trial of first-in-class biased GPCR ligand for heart failure

Aeterna Zentaris receives advice from the EMA for phase III perifosine program

Cyplasin signs term sheet with vaccine company to license AAD technology

Companies invest in Avraham to pursue phase IIb ladostigil trial in Alzheimer's disease

Bihormonal closed-loop artificial pancreas for type 1 diabetes evaluated in clinical settings

EntreMed begins phase II ENMD-981693 trial in ovarian cancer

QRxPharma completes first of two pivotal phase III trials of MoxDuo IR for pain

Aveo receives milestone payment from Biogen Idec for erbB-3 antibody program

Daiichi Sankyo launches Rezaltas tablets in Japan for hypertension

Lyrica approved in Japan to treat postherpetic neuralgia

AZD-7295 well tolerated in HCV and active against HCV genotype 1b

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...